BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D, Roviello F, Generali D. Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016;372:187-191. [PMID: 26797419 DOI: 10.1016/j.canlet.2016.01.014] [Cited by in Crossref: 82] [Cited by in F6Publishing: 98] [Article Influence: 13.7] [Reference Citation Analysis]
Number Citing Articles
1 Wan Y, Chen H, Liu X, Gu W, Lu Y. Elevated pretreatment neutrophil-to-lymphocyte ratio indicate low survival rate in apatinib-treated patients with non-small cell lung cancer: A STROBE-compliant article. Medicine 2022;101:e32043. [DOI: 10.1097/md.0000000000032043] [Reference Citation Analysis]
2 Xiang Z, Deng X, He W, Yang Q, Ni L, Dehghan Shasaltaneh M, Maghsoudloo M, Yang G, Wu J, Imani S, Wen Q. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Ann Med 2022;54:1357-71. [PMID: 35543207 DOI: 10.1080/07853890.2022.2071977] [Reference Citation Analysis]
3 Zhang Y, Zhou L, Xu Y, Zhou J, Jiang T, Wang J, Li C, Sun X, Song H, Song J. Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer. Angiogenesis 2022. [PMID: 35503397 DOI: 10.1007/s10456-022-09839-4] [Reference Citation Analysis]
4 Jing C, Wang J, Zhu M, Bai Z, Zhao B, Zhang J, Yin J, Yang X, Liu Z, Zhang Z, Deng W. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. Cancer Immunol Immunother 2022. [PMID: 35304622 DOI: 10.1007/s00262-022-03174-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Yang JR, Zhou DY, Wu Y, Zhu Y, Lin ZY, Zhang T, Yu DD. The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib. J Cancer 2022;13:15-20. [PMID: 34976167 DOI: 10.7150/jca.65339] [Reference Citation Analysis]
6 Li L, Zheng J, Liu Z, Huang Y, Xiao J, Wang S, Yu Q, Zhang Q, Hu X, Zhao W, Hou W, (Spring) Kong F, Yu J, Yuan S. Pre-treatment 18F-RGD Uptake may Predict Adverse Events during Apatinib Antiangiogenic Therapy. Clinical Oncology 2022. [DOI: 10.1016/j.clon.2022.01.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chen L, Sun T, Wu L, Zhang W, Ren Y, Xiang D, Liang B, Zheng C. The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma. J Oncol 2021;2021:8169012. [PMID: 34840572 DOI: 10.1155/2021/8169012] [Reference Citation Analysis]
8 Jing C, Bai Z, Zhang J, Jiang H, Yang X, Yan S, Yin J, Cai J, Zhang Z, Deng W. Apatinib plus S-1 for previously treated, advanced gastric or gastro-oesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. J Gastrointest Oncol 2021;12:2035-44. [PMID: 34790371 DOI: 10.21037/jgo-21-186] [Reference Citation Analysis]
9 Tian Z, Niu X, Yao W. Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review. Front Oncol 2021;11:749083. [PMID: 34676173 DOI: 10.3389/fonc.2021.749083] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
10 Al-Sanea MM, Chilingaryan G, Abelyan N, Sargsyan A, Hovhannisyan S, Gasparyan H, Gevorgyan S, Albogami S, Ghoneim MM, Farag AK, Mohamed AAB, El-Damasy AK. Identification of Novel Potential VEGFR-2 Inhibitors Using a Combination of Computational Methods for Drug Discovery. Life (Basel) 2021;11:1070. [PMID: 34685441 DOI: 10.3390/life11101070] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Zhong N, Zhuang W, Huang Q, Wang Q, Jin W. Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31. J Cell Mol Med 2021;25:10039-48. [PMID: 34590406 DOI: 10.1111/jcmm.16926] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
12 Zhong M, Lin F, Jiang Y, Pan G, Tan J, Zhou H, Lai Q, Chen Q, Deng M, Zha J, Xu B. Therapeutic Interaction of Apatinib and Chidamide in T-Cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic Apoptosis. J Pers Med 2021;11:977. [PMID: 34683119 DOI: 10.3390/jpm11100977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Zhang F, Yin Y, Xu W, Zhou Z, Sun X, Li P. Apatinib combined with Keytruda treatment induces apoptosis of gastric carcinoma cells through CES4/miR-616-5p/DUSP2 axis. Basic Clin Pharmacol Toxicol 2021. [PMID: 34365722 DOI: 10.1111/bcpt.13641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mesquita FP, Lucena da Silva E, Souza PFN, Lima LB, Amaral JL, Zuercher W, Albuquerque LM, Rabenhorst SHB, Moreira-Nunes CA, Amaral de Moraes ME, Montenegro RC. Kinase inhibitor screening reveals aurora-a kinase is a potential therapeutic and prognostic biomarker of gastric cancer. J Cell Biochem 2021. [PMID: 34160883 DOI: 10.1002/jcb.30015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wang J, Wang C, Li Y, Li M, Zhu T, Shen Z, Wang H, Lv W, Wang X, Cheng X, Xie X. Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer. Clin Transl Med 2021;11:e425. [PMID: 34047469 DOI: 10.1002/ctm2.425] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
16 Chen S, Yao L. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway. Cancer Chemother Pharmacol 2021;88:323-34. [PMID: 33978839 DOI: 10.1007/s00280-021-04291-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
17 Chen Z, Wei X, Wang X, Zheng X, Chang B, Shen L, Zhu H, Yang M, Li S, Zheng X. NDUFA4L2 promotes glioblastoma progression, is associated with poor survival, and can be effectively targeted by apatinib. Cell Death Dis 2021;12:377. [PMID: 33828084 DOI: 10.1038/s41419-021-03646-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
18 Wu Y, Cheng G, Chen H, Wang J, Wang J, Wang W. IL-17 predicts the effect of TACE combined with apatinib in hepatocellular carcinoma. Clin Hemorheol Microcirc 2021;77:37-47. [PMID: 32651310 DOI: 10.3233/CH-200857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Li M, Pu XY, Dong LH, Chang PY. Metastatic thymic-enteric adenocarcinoma responding to chemoradiation plus anti-angiogenic therapy: A case report. World J Clin Cases 2021; 9(7): 1676-1681 [PMID: 33728312 DOI: 10.12998/wjcc.v9.i7.1676] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Feng Y, Song X, Jia R. Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma. Front Oncol 2021;11:625360. [PMID: 33747940 DOI: 10.3389/fonc.2021.625360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Luo W, Qiu J, Zheng L, Zhang T. Novel therapies targeting hypoxia mechanism to treat pancreatic cancer. Chin J Cancer Res 2021;33:216-31. [PMID: 34158741 DOI: 10.21147/j.issn.1000-9604.2021.02.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Zhou C, Shi Q, Liu J, Huang S, Yang C, Xiong B. Effect of Inhibiting Tumor Angiogenesis After Embolization in the Treatment of HCC with Apatinib-Loaded p(N-Isopropyl-Acrylamide-co-Butyl Methyl Acrylate) Temperature-Sensitive Nanogel. J Hepatocell Carcinoma 2020;7:447-56. [PMID: 33409168 DOI: 10.2147/JHC.S282209] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
23 Li N, Bai C, Zhang R, Ma L, Ren X, Zhang J, Fu Z, Zhao L. Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer. Transl Oncol 2021;14:101004. [PMID: 33383486 DOI: 10.1016/j.tranon.2020.101004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Liu G, Wang Y, Wang C, He Y, E M. Clinical efficacy and safety of apatinib as maintenance treatment in patients with advanced esophageal squamous cell carcinoma. Expert Rev Clin Pharmacol 2020;13:1423-30. [PMID: 33115264 DOI: 10.1080/17512433.2020.1844004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
25 Yang ZR, Chen ZG, Du XM, Li Y. Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo. Front Oncol 2020;10:585079. [PMID: 33365269 DOI: 10.3389/fonc.2020.585079] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
26 Su B, Huang T, Jin Y, Yin H, Qiu H, Yuan X. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways. Gastric Cancer 2021;24:352-67. [PMID: 33030616 DOI: 10.1007/s10120-020-01126-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
27 Weitao Y, Fangxing W, Qiqing C, Jiaqiang W. Efficacy and safety of apatinib in advanced sarcoma: an open-label, nonrandomized, single-center study of 45 patients. Anticancer Drugs 2019;30:e0778. [PMID: 31305297 DOI: 10.1097/CAD.0000000000000778] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
28 Wei Q, Yuan X, Li J, Xu Q, Ying J. PD-1 inhibitor combined with apatinib for advanced gastric or esophagogastric junction cancer: a retrospective study. Transl Cancer Res 2020;9:5315-22. [PMID: 35117897 DOI: 10.21037/tcr-20-1333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Chen E, Xu Z, Cao G, Chen L. Apatinib for Treatment of Locally Advanced Rectal Angiosarcoma: A Case Report. Iran Red Crescent Med J 2020;22. [DOI: 10.5812/ircmj.102087] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Cai WY, Dong ZN, Fu XT, Lin LY, Wang L, Ye GD, Luo QC, Chen YC. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer. Theranostics 2020;10:8633-47. [PMID: 32754268 DOI: 10.7150/thno.47938] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
31 Huang H, Yang Y, Zhang W, Liu X, Yang G. TTK regulates proliferation and apoptosis of gastric cancer cells through the Akt-mTOR pathway. FEBS Open Bio 2020;10:1542-9. [PMID: 32530571 DOI: 10.1002/2211-5463.12909] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
32 Shen B, Jiang H, Wang L, Qian J, Shu Y, Chen P, Mao G, Liu B, Zhang X, Liu C, Wu J, Li X, Cai W, Shen W, Wang Q, He J, Hua D, Zhang Z, Zhang Y, Feng J. Effectiveness and Safety of Apatinib in Patients with Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction: A Prospective Observation Study. Onco Targets Ther 2020;13:4457-64. [PMID: 32547076 DOI: 10.2147/OTT.S232287] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Jiang Z, Xiong H, Yang S, Lu Y, Deng Y, Yao J, Yao J. Jet-Lagged Nanoparticles Enhanced Immunotherapy Efficiency through Synergistic Reconstruction of Tumor Microenvironment and Normalized Tumor Vasculature. Adv Healthc Mater 2020;9:e2000075. [PMID: 32378352 DOI: 10.1002/adhm.202000075] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 8.5] [Reference Citation Analysis]
34 Yanwei L, Feng H, Ren P, Yue J, Zhang W, Tang P, Shang X, Pang Q, Liu D, Chen C, Pan Z, Tao YZ. Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. Oncologist 2020;25:e1464-72. [PMID: 32342599 DOI: 10.1634/theoncologist.2020-0310] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
35 Nie S, Yang G, Lu H. Current Molecular Targeted Agents for Advanced Gastric Cancer. Onco Targets Ther. 2020;13:4075-4088. [PMID: 32494161 DOI: 10.2147/ott.s246412] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
36 Li C, Tang T, Wang W. Combination Use of Tegafur and Apatinib as First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study. Gastroenterol Res Pract 2020;2020:3232950. [PMID: 32328095 DOI: 10.1155/2020/3232950] [Reference Citation Analysis]
37 Wang N, Chen S, Liu D, Guo J, Sun Y, Zhang J, Kong Q, He L. Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism. Saudi J Biol Sci 2020;27:606-10. [PMID: 32210678 DOI: 10.1016/j.sjbs.2019.11.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Guo Q, Sun Y, Kong E, Rao L, Chen J, Wu Q, Zhang T, Liu N, Li M, Sun L. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study. Medicine (Baltimore) 2020;99:e19372. [PMID: 32176061 DOI: 10.1097/MD.0000000000019372] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
39 Lan J, Lu Y, Guan Y, Chang L, Yu Z, Qian H. Identification of circulating tumor DNA using a targeted 545-gene next generation sequencing panel in patients with gastric cancer. Oncol Lett 2020;19:2251-7. [PMID: 32194723 DOI: 10.3892/ol.2020.11305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
40 Selvam C, Mock CD, Mathew OP, Ranganna K, Thilagavathi R. Discovery of Vascular Endothelial Growth Factor Receptor‐2 (VEGFR‐2) Inhibitors by Ligand‐based Virtual High Throughput Screening. Mol Inf 2020;39:1900150. [DOI: 10.1002/minf.201900150] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
41 Lu P, Yin BB. Misdiagnosis of primary intimal sarcoma of the pulmonary artery as chronic pulmonary embolism: A case report. World J Clin Cases 2020; 8(5): 986-994 [PMID: 32190637 DOI: 10.12998/wjcc.v8.i5.986] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Moschetta MG, Leonel C, Maschio-Signorini LB, Borin TF, Gelaleti GB, Jardim-Perassi BV, Ferreira LC, Sonehara NM, Carvalho LGS, Hellmén E, de Campos Zuccari DAP. Evaluation of Angiogenesis Process after Metformin and LY294002 Treatment in Mammary Tumor. Anticancer Agents Med Chem 2019;19:655-66. [PMID: 30569877 DOI: 10.2174/1871520619666181218164050] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
43 Zhou C, Yao Q, Zhang H, Guo X, Liu J, Shi Q, Huang S, Xiong B. Combining transcatheter arterial embolization with iodized oil containing Apatinib inhibits HCC growth and metastasis. Sci Rep 2020;10:2964. [PMID: 32076049 DOI: 10.1038/s41598-020-59746-1] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
44 Montenegro RC, Howarth A, Ceroni A, Fedele V, Farran B, Mesquita FP, Frejno M, Berger BT, Heinzlmeir S, Sailem HZ, Tesch R, Ebner D, Knapp S, Burbano R, Kuster B, Müller S. Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib. Oncotarget 2020;11:535-49. [PMID: 32082487 DOI: 10.18632/oncotarget.27462] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
45 Zhang C, Yu GM, Zhang M, Liu D. S-1 plus apatinib as first-line palliative treatment for stage IVB gastroesophageal junction adenocarcinoma: A case report and review of the literature. Medicine (Baltimore) 2020;99:e18691. [PMID: 31895837 DOI: 10.1097/MD.0000000000018691] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Han W, Shi L, Xie B, Wan J, Ren L, Wang Y, Chen X, Wang H. Supramolecular Engineering of Molecular Inhibitors in an Adaptive Cytotoxic Nanoparticle for Synergistic Cancer Therapy. ACS Appl Mater Interfaces 2020;12:1707-20. [PMID: 31816241 DOI: 10.1021/acsami.9b20178] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
47 Wang Y, Meng X, Zhou S, Zhu Y, Xu J, Tao R. Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study. Onco Targets Ther. 2019;12:10579-10585. [PMID: 31819537 DOI: 10.2147/ott.s226804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
48 Lv Y, Zhang Y, Zhang J, Liang N, Liu F, Liu R. Reversible posterior leukoencephalopathy syndrome following apatinib for gastric cancer in an adult: A case report and a review of the literature. Medicine (Baltimore) 2019;98:e17787. [PMID: 31725620 DOI: 10.1097/MD.0000000000017787] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
49 Wu K, Zou J, Lin C, Jie ZG. MicroRNA-140-5p inhibits cell proliferation, migration and promotes cell apoptosis in gastric cancer through the negative regulation of THY1-mediated Notch signaling. Biosci Rep 2019;39:BSR20181434. [PMID: 31123165 DOI: 10.1042/BSR20181434] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
50 Chen L, Cheng X, Tu W, Qi Z, Li H, Liu F, Yang Y, Zhang Z, Wang Z. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Cell Oncol (Dordr). 2019;42:679-690. [PMID: 31325096 DOI: 10.1007/s13402-019-00455-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 8.7] [Reference Citation Analysis]
51 Li X, He Y, Hou J, Yang G, Zhou S. A Time-Programmed Release of Dual Drugs from an Implantable Trilayer Structured Fiber Device for Synergistic Treatment of Breast Cancer. Small 2020;16:e1902262. [PMID: 31322830 DOI: 10.1002/smll.201902262] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
52 Zhang Y, Zhang M, Wang Y, Fan Y, Chen X, Yang Y, Hua Y, Xie W, Lu T, Tang W, Chen Y, Liu H. Protein-ligand interaction-guided discovery of novel VEGFR-2 inhibitors. J Biomol Struct Dyn 2020;38:2559-74. [PMID: 31232191 DOI: 10.1080/07391102.2019.1635915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
53 Tian Z, Gu Z, Wang X, Liu Z, Yao W, Wang J, Zhang P, Cai Q, Ge H. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study. Medicine (Baltimore) 2019;98:e15650. [PMID: 31083265 DOI: 10.1097/MD.0000000000015650] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
54 Xu Z, Hu C, Chen S, Zhang C, Yu J, Wang X, Lv H, Cheng X. Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil. Cancer Manag Res. 2019;11:4905-4915. [PMID: 31213909 DOI: 10.2147/cmar.s196372] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
55 Qi B, Xu X, Yang Y, Zhou Y, Chen T, Gong G, Yue X, Xu X, Hu L, He H. Discovery of thiazolidin-4-one urea analogues as novel multikinase inhibitors that potently inhibit FLT3 and VEGFR2. Bioorganic & Medicinal Chemistry 2019;27:2127-39. [DOI: 10.1016/j.bmc.2019.03.049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
56 Chen R, Chen QT, Dong YH. Clinical efficacy of apatinib in treating metastatic gastric cancer and its effect on IL-17. Oncol Lett 2019;17:5447-52. [PMID: 31186764 DOI: 10.3892/ol.2019.10270] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
57 Zhu B, Fang X, Zhang Q, Mei X, Ren G. Study of Crystal Structures, Properties, and Form Transformations among a Polymorph, Hydrates, and Solvates of Apatinib. Crystal Growth & Design 2019;19:3060-9. [DOI: 10.1021/acs.cgd.9b00397] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
58 Zhu C, Yang Q, Xu J, Zhao W, Zhang Z, Xu D, Zhang Y, Zhao E, Zhao G. Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients. J Transl Med 2019;17:109. [PMID: 30944005 DOI: 10.1186/s12967-019-1867-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
59 Liao Z, Li F, Zhang C, Zhu L, Shi Y, Zhao G, Bai X, Hassan S, Liu X, Li T, Xing P, Zhao J, Zhang J, Xing R, Teng S, Yang Y, Chen K, Yang J. Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety. Exp Mol Med 2019;51:1-11. [PMID: 30816108 DOI: 10.1038/s12276-019-0221-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
60 Guo Y, Tang J, Huang XE, Cao J. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study. Medicine (Baltimore) 2019;98:e13908. [PMID: 30732125 DOI: 10.1097/MD.0000000000013908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
61 He K, Wu L, Ding Q, Haider F, Yu H, Wang H, Xiang G. Apatinib Promotes Apoptosis of Pancreatic Cancer Cells through Downregulation of Hypoxia-Inducible Factor-1α and Increased Levels of Reactive Oxygen Species. Oxid Med Cell Longev 2019;2019:5152072. [PMID: 30863481 DOI: 10.1155/2019/5152072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
62 Liu Z, Wang C, Wu G, Cheng J. MRI analysis of hydrogel-loaded apatinib for local therapy of hepatocellular carcinoma model in nude mice. Biochem Biophys Res Commun 2019;509:529-34. [PMID: 30598262 DOI: 10.1016/j.bbrc.2018.12.120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
63 Xu DH, Li Q, Hu H, Ni B, Liu X, Huang C, Zhang ZZ, Zhao G. Transmembrane protein GRINA modulates aerobic glycolysis and promotes tumor progression in gastric cancer. J Exp Clin Cancer Res 2018;37:308. [PMID: 30541591 DOI: 10.1186/s13046-018-0974-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
64 Zhang D, Zhang C, Guo Q. [A Case Report of Primary Pulmonary Synovial Sarcoma with Postoperative Multiple Metastases Treated with Apatinib]. Zhongguo Fei Ai Za Zhi 2018;21:880-4. [PMID: 30454552 DOI: 10.3779/j.issn.1009-3419.2018.11.11] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
65 Liu Y, Zhou C, Zhang K, Feng Y, Zhang R. The combination of apatinib and S-1 for the treatment of advanced gastric cancer in China: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2018;97:e13259. [PMID: 30461630 DOI: 10.1097/MD.0000000000013259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
66 Shi JJ, Dang SS. Recent advances in molecular targeted therapy of hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2018; 26(34): 2008-2017 [DOI: 10.11569/wcjd.v26.i34.2008] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
67 Shi M, Duan G, Nie S, Shen S, Zou X. Elevated FAM3C promotes cell epithelial- mesenchymal transition and cell migration in gastric cancer. Onco Targets Ther 2018;11:8491-505. [PMID: 30584315 DOI: 10.2147/OTT.S178455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
68 Li YH, Zhou Y, Wang YW, Tong L, Jiang RX, Xiao L, Zhang GJ, Xing SS, Qian F, Feng JQ, Zhao YL, Wang JG, Wang XH. Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study. Medicine (Baltimore) 2018;97:e12222. [PMID: 30200142 DOI: 10.1097/MD.0000000000012222] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
69 Yang L, Zhu H, Luo P, Chen S, Xu Y, Wang C. Apatinib mesylate tablet in the treatment of advanced malignant melanoma. Onco Targets Ther. 2018;11:5333-5338. [PMID: 30214239 DOI: 10.2147/ott.s175507] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
70 Liu S, Shi H, Ji C, Guan W, Chen L, Sun Y, Tang L, Guan Y, Li W, Ge Y, He J, Liu S, Zhou Z. CT textural analysis of gastric cancer: correlations with immunohistochemical biomarkers. Sci Rep 2018;8:11844. [PMID: 30087428 DOI: 10.1038/s41598-018-30352-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
71 Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137-4147. [PMID: 30050305 DOI: 10.2147/ott.s172305] [Cited by in Crossref: 35] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
72 Cheng H, Sun A, Guo Q, Zhang Y. Efficacy and safety of apatinib combined with chemotherapy for the treatment of advanced gastric cancer in the Chinese population: a systematic review and meta-analysis. Drug Des Devel Ther 2018;12:2173-83. [PMID: 30034222 DOI: 10.2147/DDDT.S170678] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
73 Wang Y, Gou Q, Xu R, Chen X, Zhou Z. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. Onco Targets Ther. 2018;11:3407-3413. [PMID: 29928132 DOI: 10.2147/ott.s161023] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
74 Ding X, Sun J, Fan T, Li B. A case report of targeted therapy with apatinib in a patient with recurrent high grade glioma. Medicine (Baltimore) 2018;97:e10859. [PMID: 29851800 DOI: 10.1097/MD.0000000000010859] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
75 Li F, Liao Z, Zhang C, Zhao J, Xing R, Teng S, Zhang J, Yang Y, Yang J. Apatinib as targeted therapy for sarcoma. Oncotarget 2018;9:24548-60. [PMID: 29849960 DOI: 10.18632/oncotarget.24647] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
76 Li H, Fan Y, Yang F, Zhao L, Cao B. The coordinated effects of Apatinib and Tripterine on the proliferation, invasiveness and apoptosis of human hepatoma Hep3B cells. Oncol Lett 2018;16:353-61. [PMID: 29928421 DOI: 10.3892/ol.2018.8656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Chang X, Wang Y, Yu HP, Zhang WH, Yang XL, Guo Z. CT-guided percutaneous cryoablation for palliative therapy of gastric cancer liver metastases. Cryobiology. 2018;82:43-48. [PMID: 29679550 DOI: 10.1016/j.cryobiol.2018.04.010] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
78 Ma JL, Zhang T, Suo FZ, Chang J, Wan XB, Feng XJ, Zheng YC, Liu HM. Lysine-specific demethylase 1 activation by vitamin B2 attenuates efficacy of apatinib for proliferation and migration of gastric cancer cell MGC-803. J Cell Biochem. 2018;119:4957-4966. [PMID: 29384217 DOI: 10.1002/jcb.26741] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
79 Zhang H, Cao Y, Chen Y, Li G, Yu H. Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway. Oncol Lett. 2018;15:5739-5743. [PMID: 29552208 DOI: 10.3892/ol.2018.8031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
80 Li L, Xiao S, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Zhang X, Chang Y, Nan F, Yan J, Li Z, Shi M, Young KH, Zhang M. An open label, single-armed, exploratory study of apatinib (a novel VEGFR-2 tyrosine kinase inhibitor) in patients with relapsed or refractory non-Hodgkin lymphoma. Oncotarget 2018;9:16213-9. [PMID: 29662638 DOI: 10.18632/oncotarget.23806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
81 Zhao H, Sun D, Tang Y, Yao J, Yuan X, Zhang M. Thermo/pH dual-responsive core–shell particles for apatinib/doxorubicin controlled release: preparation, characterization and biodistribution. J Mater Chem B 2018;6:7621-33. [DOI: 10.1039/c8tb02334d] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
82 Farran B, Müller S, Montenegro RC. Gastric cancer management: Kinases as a target therapy. Clin Exp Pharmacol Physiol 2017;44:613-22. [PMID: 28271563 DOI: 10.1111/1440-1681.12743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 4.5] [Reference Citation Analysis]
83 Roviello G, Roviello F, Polom K, Generali D. Apatinib in metastatic gastric cancer: can paclitaxel make the difference? Anticancer Drugs 2016;27:809. [PMID: 27306082 DOI: 10.1097/CAD.0000000000000380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
84 Zhao F, Tian W, Zeng M, Xia J, Hu H, Hao X, Han L, Liu H, He Y, Zhu X, Liang L, Ao R, Wei M, Deng L, Wei Y. Apatinib alone or combined with radiotherapy in metastatic prostate cancer: Results from a pilot, multicenter study. Oncotarget 2017;8:110774-84. [PMID: 29340015 DOI: 10.18632/oncotarget.22719] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
85 Wu JQ, Zhai J, Li CY, Tan AM, Wei P, Shen LZ, He MF. Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. J Exp Clin Cancer Res. 2017;36:160. [PMID: 29141689 DOI: 10.1186/s13046-017-0631-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 10.4] [Reference Citation Analysis]
86 Mbele M, Hull R, Dlamini Z. African medicinal plants and their derivatives: Current efforts towards potential anti-cancer drugs. Experimental and Molecular Pathology 2017;103:121-34. [DOI: 10.1016/j.yexmp.2017.08.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
87 Liu C, Xing W, Si T, Yu H, Guo Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 2017;8:100734-45. [PMID: 29246017 DOI: 10.18632/oncotarget.20140] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
88 Sobhani N, Generali D, Roviello G. PAK6-Associated Support Vector Machine Classifier: A New Way to Evaluate Response and Survival of Gastric Cancer Treated by 5-FU/Oxaliplatin Chemotherapy. EBioMedicine 2017;22:18-9. [PMID: 28688823 DOI: 10.1016/j.ebiom.2017.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
89 Li F, Liao Z, Zhao J, Zhao G, Li X, Du X, Yang Y, Yang J. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017;8:64471-64480. [PMID: 28969086 DOI: 10.18632/oncotarget.16293] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 7.8] [Reference Citation Analysis]
90 Roviello G, Polom K, Roviello F, Marrelli D, Multari AG, Paganini G, Pacifico C, Generali D. Targeting VEGFR-2 in Metastatic Gastric Cancer: Results From a Literature-Based Meta-Analysis. Cancer Invest 2017;35:187-94. [PMID: 28165839 DOI: 10.1080/07357907.2016.1276185] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
91 Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, Yang Y, Li Q. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol 2017;143:361-8. [PMID: 27798730 DOI: 10.1007/s00432-016-2296-z] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
92 Jeong JH, Nguyen HK, Lee JE, Suh W. Therapeutic effect of apatinib-loaded nanoparticles on diabetes-induced retinal vascular leakage. Int J Nanomedicine 2016;11:3101-9. [PMID: 27462154 DOI: 10.2147/IJN.S108452] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
93 Petrioli R, Roviello G, Zanotti L, Roviello F, Polom K, Bottini A, Marano L, Francini E, Marrelli D, Generali D. Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016;102:82-88. [PMID: 27083592 DOI: 10.1016/j.critrevonc.2016.04.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
94 Lu W, Ke H, Qianshan D, Zhen W, Guoan X, Honggang Y. Apatinib has anti-tumor effects and induces autophagy in colon cancer cells. Iran J Basic Med Sci 2017;20:990-5. [PMID: 29085592 DOI: 10.22038/IJBMS.2017.9263] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
95 Liao Z, Li T, Zhang C, Liu X, Xing R, Teng S, Yang Y, Zhao G, Bai X, Zhao J, Yang J. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy. Cancer Biol Med 2020;17:501-12. [PMID: 32587785 DOI: 10.20892/j.issn.2095-3941.2019.0397] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Reference Citation Analysis]